SRRK

Scholar Rock Holding Corp

42.91

Nov 02 • 3:59 PM ET -0.99 (-2.26%)

43.07

Aftermarket • 7:30 PM ET +0.16 (0.37%)

Healthcare Biotechnology USA Mid NASD

Peers: BHVN PTCT DYN BIIB SRPT EWTX REGN CYTK NVS KROS

| Held by: VTI IWM XBI VB VXF IWO IBB VBK VTWO SCHA

Scroll to Statements

Index	RUT
Market Cap	5.23B
Enterprise Value	4.94B
Income	-408.59M
Sales	0.00M
Book/sh	2.09
Cash/sh	4.04
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	289
IPO	May 24, 2018

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	20.56
P/C	10.62
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	7.02
Current Ratio	7.02
Debt/Eq	0.80
LT Debt/Eq	0.78
Option/Short	Yes / Yes

EPS (ttm)	-3.45
EPS next Y	-2.61
EPS next Q	-0.85
EPS this Y	-1.37%
EPS next Y	21.73%
EPS next 5Y	27.07%
EPS past 3/5Y	-13.45% -3.21%
Sales past 3/5Y	- -
EPS Y/Y TTM	-14.40%
Sales Y/Y TTM	-
EPS Q/Q	13.82%
Sales Q/Q	-
Earnings	Nov 10 BMO
EPS/Sales Surpr.	0.06% -

Insider Own	17.26%
Insider Trans	1.31%
Inst Own	101.08%
Inst Trans	4.36%
ROA	-94.63%
ROE	-167.77%
ROIC	-90.54%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	2.39%
SMA50	-10.97%
SMA200	-10.95%
Trades

Shs Outstand	121.60M
Shs Float	100.76M
Short Float	22.01%
Short Ratio	13.36
Short Interest	22.18M
52W High	61.76 -30.52%
52W Low	27.07 58.51%
Volatility	4.10% 4.39%
ATR (14)	1.90
RSI (14)	45.31
Beta	0.79
Rel Volume	0.56
Avg Volume	1.66M
Volume	932,077

Perf Week	2.88%
Perf Month	-8.33%
Perf Quarter	-10.21%
Perf Half Y	-7.68%
Perf YTD	-2.59%
Perf Year	44.87%
Perf 3Y	242.18%
Perf 5Y	54.41%
Perf 10Y	-
Recom	1.11
Target Price	69.12
Prev Close	43.90
Price	42.91
Change %	-2.26%

Consensus

Strong Buy

Avg. Price Target

$69.12

Implied Upside

+61.1%

Analysts12incl. previous ratings

Rating Distribution11 Buy · 1 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Sep 15, 2026	Downgrade	BBarclays	Overweight → Equal Weight	$58	+35.2%
Apr 21, 2026	Initiated	CCanaccord Genuity	Buy	$62	+44.5%
Jan 09, 2026	Initiated	CCitigroup	Buy	$55	+28.2%
Nov 18, 2025	Initiated	WWolfe Research	Outperform	$42	-2.1%
Oct 09, 2025	Initiated	BBofA Securities	Buy	$53	+23.5%
Sep 17, 2025	Initiated	BBarclays	Overweight	$45	+4.9%
Sep 15, 2025	Initiated	LLeerink Partners	Outperform	$51	+18.9%
Aug 21, 2025	Resumed	JJefferies	Buy	$50	+16.5%
Jul 30, 2025	Resumed	RRaymond James	Strong Buy	$53	+23.5%
Jul 17, 2025	Initiated	CCantor Fitzgerald	Overweight
Nov 26, 2024	Reiterated	HH.C. Wainwright	Buy	$40 → $50	+16.5%
Oct 07, 2024	Reiterated	HH.C. Wainwright	Buy	$30 → $35	-18.4%
Mar 28, 2024	Initiated	RRaymond James	Strong Buy	$30	-30.1%
Oct 25, 2023	Upgrade	JJefferies	Hold → Buy	$20	-53.4%
Apr 03, 2023	Resumed	PPiper Sandler	Overweight	$26	-39.4%
Sep 19, 2022	Resumed	HH.C. Wainwright	Buy	$30	-30.1%
Jul 12, 2022	Initiated	TTruist	Buy	$20	-53.4%
Mar 23, 2022	Initiated	HH.C. Wainwright	Buy	$24	-44.1%
Dec 22, 2021	Downgrade	JJefferies	Buy → Hold	$52 → $28	-34.7%
Nov 19, 2021	Initiated	PPiper Sandler	Overweight	$56	+30.5%

Oct-20-26 08:00AM	Scholar Rock to Report Third Quarter 2026 Financial Results on November 10, 2026 (Business Wire)
Oct-16-26 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Oct-08-26 08:00AM	Scholar Rock Resubmits Apitegromab Marketing Authorisation Application (MAA) to European Medicines Agency (EMA) for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA) (Business Wire)
Oct-02-26 09:00AM	3 drug targets pharma is betting on next (Pharma Voice)
Sep-28-26 06:44AM	FDA Decision Watch: BMY, EGTX Face Key Decisions This Week As BFRI, SRRK And MIRM Score Early Approvals (Stocktwits)
12:00PM	Loading…
Sep-21-26 12:00PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-18-26 06:43AM	This week in charts: GSKs China deals, the $300M IPO club and selling the news (BioPharma Dive)
Sep-14-26 04:30PM	SRRK Shares Pull Back After FDA Approval For Genetic Disease Drug But Wall Street Hikes Price Targets (Stocktwits) -6.42%
08:08AM	Scholar Rock Shares Rise 9.1% After FDA Approves ISEMBYLD for Spinal Muscular Atrophy (InvestorsHub)
07:41AM	Premarket movers: AI stocks slide on warnings, Rumble, Scholar Rock jump (Investing.com)
05:00AM	Scholar Rock SMA drug approved by FDA (BioPharma Dive)
Sep-11-26 07:31PM	Second Times The Charm: FDA Clears Scholar Rocks SMA Drug Ahead Of Deadline, SRRK Soars 15% After-Hours (Stocktwits)
06:25PM	Scholar Rock Announces FDA Approval of ISEMBYLD (apitegromab-mstn), the First and Only Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (SMA) (Business Wire)
Sep-02-26 08:00AM	Scholar Rock Receives FDA Fast Track Designation for Apitegromab Facioscapulohumeral Muscular Dystrophy (FSHD) Program as Participant Dosing Commences in Phase 2 FORGE Trial (Business Wire)
Aug-27-26 08:00AM	Scholar Rock to Present at Upcoming Investor Conferences (Business Wire)
05:50PM	Loading…
Aug-21-26 05:50PM	SRRK Stock Gains After Company Drops Troubled Novo Nordisk-Owned Plant From FDA Filing (Stocktwits)
09:06AM	Scholar Rock Provides Update on Global Apitegromab Regulatory Progress Across U.S., Europe, and Japan (Business Wire)
Aug-14-26 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-07-26 04:20PM	Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by September 30, 2026 Action Date (Business Wire)
Aug-06-26 03:02PM	Scholar Rock Holding Corp (SRRK) (Q2 2026) Earnings Call Highlights: Dual Paths to FDA Approval ... (GuruFocus.com) +9.96%
07:00AM	Scholar Rock Reports Second Quarter 2026 Financial Results and Recent Business Highlights (Business Wire)
Jul-29-26 08:00AM	Scholar Rock to Present at the Canaccord Genuity 46th Annual Growth Conference (Business Wire)
Jul-20-26 08:00AM	Scholar Rock Provides Update on Timing of Committee for Medicinal Products for Human Use (CHMP) Opinion for Apitegromab Marketing Authorisation Application (MAA) for Spinal Muscular Atrophy (SMA) (Business Wire)
04:54AM	Bristol Myers to build powerful AI factory; Samsung Biologics bids for peptide maker (BioPharma Dive)
Jul-17-26 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-16-26 08:00AM	Scholar Rock to Report Second Quarter 2026 Financial Results on August 6, 2026 (Business Wire)
Jun-22-26 08:00AM	Scholar Rock to Showcase Neuromuscular Research Portfolio at 2026 Annual Cure SMA Research and Clinical Care Meeting and 2026 International Research Congress on FSHD (Business Wire)
Jun-12-26 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-26-26 09:30AM	Scholar Rock to Present at the Goldman Sachs 47th Annual Global Healthcare Conference (Business Wire) +7.02%
May-20-26 08:00AM	Scholar Rock to Present at the 2026 Jefferies Global Healthcare Conference (Business Wire)
04:15PM	Loading…
May-15-26 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-07-26 07:00AM	Scholar Rock Reports First Quarter 2026 Financial Results and Recent Business Highlights (Business Wire)
Apr-29-26 08:00AM	Scholar Rock to Present at the BofA Securities 2026 Health Care Conference (Business Wire)
Apr-17-26 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-16-26 08:00AM	Scholar Rock to Report First Quarter 2026 Financial Results on May 7, 2026 (Business Wire)
Mar-31-26 07:00AM	Scholar Rock Resubmits Biologics License Application (BLA) to FDA for Apitegromab for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA) (Business Wire) +14.11%
Mar-13-26 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-03-26 01:30PM	Scholar Rock Q4 Earnings Call Highlights (MarketBeat)
07:00AM	Scholar Rock Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights (Business Wire)
Feb-18-26 08:00AM	Scholar Rock to Present at Upcoming Investor Conferences (Business Wire)
Feb-13-26 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-10-26 08:00AM	Scholar Rock to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026 (Business Wire)
Jan-16-26 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-12-26 07:00AM	Scholar Rock Highlights 2026 Strategic Priorities (Business Wire)
Jan-05-26 08:00AM	Scholar Rock to Present at the 44th Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-13-25 10:57AM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-18-25 08:00AM	Scholar Rock to Present at Upcoming Investor Conferences (Business Wire) +9.14%
Nov-16-25 11:16AM	Scholar Rock (SRRK) Soars 29% as Drug Candidate Progresses (Insider Monkey)
Nov-15-25 07:07AM	Scholar Rock (SRRK) Climbs 24% on Drug Candidate Progress (Insider Monkey)
Nov-14-25 02:02PM	Scholar Rock Holding Corp (SRRK) Q3 2025 Earnings Call Highlights: Strategic Moves and ... (GuruFocus.com) +24.41%
07:00AM	Scholar Rock Reports Third Quarter 2025 Financial Results and Recent Business Highlights (Business Wire)
Nov-12-25 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
08:15AM	3 Beaten-Down Stocks With Rebound Potential This Earnings Season (MarketBeat)
Nov-04-25 08:00AM	Scholar Rock to Present at the 2025 Jefferies Global Healthcare Conference (Business Wire)
Oct-23-25 08:00AM	Scholar Rock to Report Third Quarter 2025 Financial Results on November 14, 2025 (Business Wire)
Oct-17-25 06:15PM	Dayforce, Scholar Rock, and More Stocks See Action From Activist Investors (Barrons.com) -5.10%
04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
09:45AM	Insiders Bet Big on These 3 Fintech and Biotech Stocks (24/7 Wall St.)
Oct-13-25 05:22PM	Why Scholar Rock Stock Got Socked on Monday (Motley Fool) -13.14% -6.93%
Oct-09-25 05:07PM	Why Scholar Rock Stock Raced 6% Higher Today (Motley Fool) +5.94%
Oct-08-25 01:10PM	Scholar Rock Holding Stock Scores RS Rating Upgrade (Investor's Business Daily)
Sep-23-25 04:06PM	Scholar Rock, A Top 10% Stock, Reverses Higher Despite A Surprise Setback (Investor's Business Daily)
10:04AM	Scholar Rock, A Top 10% Stock, Dives After Catalent Issues Hamper SMA Drug (Investor's Business Daily)
07:11AM	US FDA declines to approve Scholar Rock's muscle weakness drug; shares fall (Reuters)
07:00AM	FDA Issues Complete Response Letter (CRL) for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA) Solely Related to Observations Identified at Catalent Indiana LLC Fill-Finish Facility (Business Wire)
06:19AM	Scholar Rock SMA drug rejected by FDA over manufacturing concerns (BioPharma Dive)
Sep-15-25 04:54PM	Why Scholar Rock Stock Bounced Higher on Monday (Motley Fool) +6.32%
Sep-12-25 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-11-25 03:31AM	Can Apitegromab Approval Turn Scholar Rock (SRRK) Into the Next Biotech Multibagger? (Insider Monkey)
Aug-21-25 12:18PM	Scholar Rock (SRRK) Jumps 14% on Bargain-Hunting, Price Down 20.4% YTD (Insider Monkey)
Aug-15-25 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
09:20AM	Veru Announces Novel Modified-Release Oral Formulation for Enobosarm (Zacks)
Aug-14-25 08:00AM	Pivotal SAPPHIRE Trial Data Published in The Lancet Neurology: Apitegromab Demonstrated Significant Motor Function Gains for Children and Adults with SMA on SMN-Targeted Treatment (Business Wire)
Aug-11-25 08:21PM	Scholar Rock's Apitegromab Maintains Lean Mass In Phase 2 EMBRAZE Trial With Tirzepatide-Induced Weight Loss (Insider Monkey)
Aug-06-25 05:10PM	Why Scholar Rock Stock Wilted on Wednesday (Motley Fool) -6.40% -9.30%
07:00AM	Scholar Rock Reports Second Quarter 2025 Financial Results and Highlights Business Progress (Business Wire)
Jul-21-25 08:00AM	Scholar Rock to Host Conference Call to Discuss Second Quarter 2025 Financial Results and Provide Business Update on August 6, 2025 (Business Wire)
Jul-18-25 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-23-25 08:00AM	Scholar Rock to Present Comprehensive Update at 2025 Annual Cure SMA Research and Clinical Care Meeting, Including Positive Results from Pivotal Phase 3 SAPPHIRE Trial (Business Wire)
Jun-20-25 03:45PM	Muscle-preserving drugs could generate over $30 billion in sales by 2035, TD Cowen says (Reuters) -6.28%
Jun-19-25 02:01PM	Scholar Rock (SRRK) Jumps 16.6% After Successful Weight Loss Drug Trial (Insider Monkey)
Jun-18-25 01:41PM	Why Scholar Rock Shares Are Soaring Today (Motley Fool) +16.60%
11:40AM	Scholar Rock Stock Soars on Biopharma Firm's Weight-Loss Drug Trial Results (Investopedia)
07:42AM	Scholar Rock drug preserves muscle in obesity trial (BioPharma Dive)
07:00AM	Scholar Rock Reports Positive Phase 2 EMBRAZE Trial Results Demonstrating Statistically Significant Preservation of Lean Mass with Apitegromab During Tirzepatide-Induced Weight Loss (Business Wire)
Jun-13-25 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-05-25 08:00AM	Scholar Rock to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference (Business Wire) +11.13%
Jun-02-25 08:00AM	Scholar Rock Appoints Rebecca McLeod Chief Brand Officer and U.S. General Manager (Business Wire)
May-28-25 08:00AM	Scholar Rock to Present at the Jefferies Global Healthcare Conference (Business Wire) -5.28%
May-16-25 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-15-25 03:10AM	Scholar Rock Holding Corp (SRRK) Q1 2025 Earnings Call Highlights: Strong Progress and ... (GuruFocus.com)
01:39AM	Q1 2025 Scholar Rock Holding Corp Earnings Call (Thomson Reuters StreetEvents)
May-14-25 07:00AM	Scholar Rock Reports First Quarter 2025 Financial Results and Highlights Business Progress (Business Wire)
May-13-25 09:24AM	What To Expect From Scholar Rock Holding Corp (SRRK) Q1 2025 Earnings (GuruFocus.com)
May-07-25 08:00AM	Scholar Rock to Host Conference Call to Discuss First Quarter 2025 Financial Results and Provide Business Update on May 14, 2025 (Business Wire)
May-06-25 04:15PM	Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -10.01%
Apr-28-25 07:08PM	Why Scholar Rock Stock Took a Knock on Monday (Motley Fool)
06:50AM	Scholar Rock Appoints David L. Hallal as Chief Executive Officer; Also Announces Addition of Three Key Leaders to Scale for Next Phase of Growth (Business Wire)
Apr-23-25 06:34PM	Why Scholar Rock Holding Stock Topped the Market Today (Motley Fool) +5.72%

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
AKKARAJU SRINIVAS	Director	Oct 26 '26	Buy	41.59	146,970	6,112,482	6,380,517	Oct 27 07:47 PM
AKKARAJU SRINIVAS	Director	Oct 23 '26	Buy	41.32	142,500	5,887,440	6,331,529	Oct 27 07:47 PM
Katie Peng	Director	Oct 01 '26	Proposed Sale	48.32	1,006	48,610		Oct 01 04:19 PM
FLIER JEFFREY S.	Director	Jul 01 '26	Sale	53.88	3,053	164,490	27,856	Jul 06 04:30 PM
Gilman Michael	Director	Jul 01 '26	Sale	53.87	2,544	137,058	59,511	Jul 06 04:30 PM
Burow Kristina	Director	Jul 01 '26	Sale	53.74	3,053	164,064	114,657	Jul 06 04:30 PM
Reed Joshua	Director	Jul 01 '26	Sale	53.74	3,053	164,067	19,518	Jul 06 04:30 PM
Peng Katie	Director	Jul 01 '26	Sale	53.88	5,446	293,405	34,301	Jul 06 04:30 PM
Mohammed Qatanani	Officer	Jul 06 '26	Proposed Sale	54.68	11,704	639,975		Jul 06 04:22 PM
Joshua Reed	Director	Jul 01 '26	Proposed Sale	54.79	3,053	167,274		Jul 01 04:58 PM
Jeffrey S. Flier	Director	Jul 01 '26	Proposed Sale	54.79	3,053	167,274		Jul 01 04:55 PM
Kristina Burow	Director	Jul 01 '26	Proposed Sale	54.79	3,053	167,274		Jul 01 04:52 PM
Michael Gilman	Director	Jul 01 '26	Proposed Sale	54.79	2,544	139,385		Jul 01 04:46 PM
Katie Peng	Director	Jul 01 '26	Proposed Sale	54.79	5,446	298,386		Jul 01 04:44 PM
Burow Kristina	Director	Apr 23 '26	Option Exercise	9.14	89,800	820,324	110,871	Apr 24 04:05 PM
Woods Keith	Chief Operating Officer	Apr 16 '26	Sale	49.57	10,220	506,651	620,055	Apr 20 06:12 PM
Vaishnaw Akshay	President of R&D	Apr 16 '26	Sale	49.57	12,246	607,089	630,542	Apr 20 06:10 PM
Sinha Vikas	Chief Financial Officer	Apr 16 '26	Sale	49.57	10,410	516,071	619,856	Apr 20 06:09 PM
Hallal David	Chief Executive Officer	Apr 16 '26	Sale	49.57	30,615	1,517,723	1,639,034	Apr 20 06:08 PM
Mohammed Qatanani	Officer	Apr 06 '26	Proposed Sale	50.01	23,408	1,170,634		Apr 06 04:11 PM
Qatanani Mo	CHIEF SCIENTIFIC OFFICER	Feb 23 '26	Sale	47.07	8,484	399,351	98,445	Feb 25 05:55 PM
Mohammed Qatanani	Officer	Feb 23 '26	Proposed Sale	48.32	8,484	409,947		Feb 23 04:05 PM
Marantz Jing L.	CHIEF MEDICAL OFFICER	Feb 17 '26	Sale	46.53	4,157	193,418	126,012	Feb 19 04:30 PM
Ho Junlin	GENERAL COUNSEL	Feb 17 '26	Sale	46.53	9,580	445,740	241,545	Feb 19 04:30 PM
Parlavecchio Caryn	CHRO	Feb 17 '26	Sale	46.53	9,035	420,382	169,087	Feb 19 04:30 PM
Qatanani Mo	CHIEF SCIENTIFIC OFFICER	Feb 17 '26	Sale	46.53	7,989	371,714	106,929	Feb 19 04:30 PM
Qatanani Mo	CHIEF SCIENTIFIC OFFICER	Jan 22 '26	Sale	46.71	14,898	695,938	85,660	Jan 23 04:30 PM
Mohammed Qatanani	Officer	Jan 22 '26	Proposed Sale	46.05	14,898	686,053		Jan 22 04:14 PM
Qatanani Mo	CHIEF SCIENTIFIC OFFICER	Jan 16 '26	Sale	44.48	8,406	373,880	100,558	Jan 21 07:52 PM
Parlavecchio Caryn	CHRO	Jan 16 '26	Sale	44.48	6,600	293,553	148,864	Jan 21 07:51 PM
Marantz Jing L.	CHIEF MEDICAL OFFICER	Jan 16 '26	Sale	44.48	5,798	257,882	95,687	Jan 21 07:50 PM
Ho Junlin	GENERAL COUNSEL	Jan 16 '26	Sale	44.48	8,016	356,533	214,553	Jan 21 07:50 PM
Qatanani Mo	CHIEF SCIENTIFIC OFFICER	Jan 14 '26	Option Exercise	18.53	13,112	242,961	122,076	Jan 16 06:37 PM
Qatanani Mo	CHIEF SCIENTIFIC OFFICER	Jan 14 '26	Sale	45.20	13,112	592,611	108,964	Jan 16 06:37 PM
Sinha Vikas	Chief Financial Officer	Jan 13 '26	Sale	42.70	16,755	715,438	583,245	Jan 15 07:58 PM
Woods Keith	Chief Operating Officer	Jan 13 '26	Sale	42.70	16,746	715,054	583,254	Jan 15 07:57 PM
Vaishnaw Akshay	President of R&D	Jan 13 '26	Sale	42.70	20,438	872,703	595,767	Jan 15 07:56 PM
Hallal David	Chief Executive Officer	Jan 13 '26	Sale	42.70	57,450	2,453,115	1,541,645	Jan 15 07:54 PM
Peng Katie	Director	Dec 16 '25	Sale	44.09	1,006	44,352	32,908	Dec 18 04:30 PM
Katie Peng	Director	Dec 16 '25	Proposed Sale	45.24	1,006	45,511		Dec 16 06:02 PM
Qatanani Mo	CHIEF SCIENTIFIC OFFICER	Dec 04 '25	Option Exercise	21.21	136,462	2,894,077	245,426	Dec 05 04:53 PM
Qatanani Mo	CHIEF SCIENTIFIC OFFICER	Dec 04 '25	Sale	45.21	136,462	6,169,788	108,964	Dec 05 04:53 PM
Mohammed Qatanani	Officer	Dec 04 '25	Proposed Sale	43.01	149,574	6,433,178		Dec 04 04:19 PM

Scholar Rock Holding Corp. is a biopharmaceutical company. It engages in the business of discovering, developing, and delivering innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company was founded by Timothy A. Springer and Leonard I. Zon in October 2012 and is headquartered in Cambridge, MA.

CEO & Chairman of the BoardMr. David L. Hallal

CPAMr. Vikas Sinha C.A.

Chief Operating OfficerMr. Robert Keith Woods

Ph.D.Dr. Akshay Krishnadas Vaishnaw M.D.

Interim Principal Financial & Accounting OfficerMs. Erin Moore CPA

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SRRK

Scholar Rock Holding Corp

Upgrade your Finviz experience